Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1931-1934

  Jida, Masaru ^a   Toyooka, Shinichi ^a   Mitsudomi, Tetsuya ^c   Takano, Toshimi ^e   Matsuo, Keitaro ^c   Hotta, Katsuyuki ^b   Tsukuda, Kazunori ^a   Kubo, Takafumi ^a   Yamamoto, Hiromasa ^a   Yamane, Masaomi ^a   Oto, Takahiro ^a   Sano, Yoshifumi ^a   Kiura, Katsuyuki ^b   Yatabe, Yasushi ^d   Ohe, Yuichiro ^e   Date, Hiroshi ^f   Miyoshi, Shinichiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c National Cancer Center Hospital ^*  (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LEUCINE;

ACCURACY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; SMOKING; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 70349591635     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01273.x     Document Type: Article

References (22)

1. Rusch V, Baselga J, Cordon-Cardo C. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53:2379-85.
2. Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-39.
3. Paez JG, Janne PA, Lee JC. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-500.
4. Shigematsu H, Lin L, Takahashi T. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-46.
5. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006, 20:1496-510.
6. Fukuoka M, Yano S, Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21:2237-46.
7. Mitsudomi T, Kosaka T, Endoh H. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-20.
8. Takano T, Ohe Y, Sakamoto H. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-37.
9. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-23.
10. Tokumo M, Toyooka S, Kiura K. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005, 11:1167-73.
11. Pham D, Kris MG, Riely GJ. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006, 24:1700-4.
12. Toyooka S, Takano T, Kosaka T. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 2008, 99:303-8.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-14.
14. Ichihara S, Toyooka S, Fujiwara Y. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 2007, 120:1239-47.
15. Asano H, Toyooka S, Tokumo M. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006, 12:43-8.
16. Perkins NJ, Schisterman EF. The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006, 163:670-5.
17. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988, 240:1285-93.
18. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003, 29:1043-51.
19. Hotta K, Kiura K, Takigawa N. Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Lung Cancer 2008, 62:236-41.
20. Matsuo K, Ito H, Yatabe Y. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 2007, 98:96-101.
21. Matsumoto S, Iwakawa R, Takahashi K. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007, 26:5911-8.
22. Toyooka S, Maruyama R, Toyooka KO. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003, 103:153-60.